Regenxbio Inc [RGNX] stock prices are up 9.16% to $20.02 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RGNX shares have gain 7.98% over the last week, with a monthly amount glided 57.39%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights. In a post published today on Yahoo Finance, Focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation.
From an analyst’s perspective:
Previously, Stifel started tracking the stock with Buy rating on November 01, 2023, and set its price target to $35. On June 02, 2023, Robert W. Baird initiated with a Outperform rating and assigned a price target of $42 on the stock. Berenberg started tracking the stock assigning a Buy rating and suggested a price target of $61 on June 23, 2022. Wedbush initiated its recommendation with a Neutral and recommended $29 as its price target on December 15, 2021. In a note dated January 06, 2021, Raymond James upgraded an Strong Buy rating on this stock but restated the target price of $60.
The stock price of Regenxbio Inc [RGNX] has been fluctuating between $11.83 and $25.32 over the past year. Regenxbio Inc [NASDAQ: RGNX] shares were valued at $20.02 at the most recent close of the market.
Analyzing the RGNX fundamentals
The Regenxbio Inc [NASDAQ:RGNX] reported sales of 99.37M for trailing twelve months, representing a surge of 9.06%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.99 points at the first support level, and at 17.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.66, and for the 2nd resistance point, it is at 21.31.
Regenxbio Inc [RGNX] reported earnings per share of -$1.41 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.52/share, meaning a difference of $0.11 and a surprise factor of 7.20%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$1.66 per share as compared to estimates of -$1.38 per share, a difference of -$0.28 representing a surprise of -20.30%.
Ratios To Look Out For
It’s worth pointing out that Regenxbio Inc [NASDAQ:RGNX]’s Current Ratio is 2.87. Also, the Quick Ratio is 2.87, while the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 8.86, the price to book ratio is 2.43.
Transactions by insiders
Recent insider trading involved Mills Kenneth T., President and CEO, that happened on Feb 14 when 15000.0 shares were sold. President and CEO, Mills Kenneth T. completed a deal on Jan 16 to sell 45000.0 shares. Meanwhile, Chief Medical Officer PAKOLA STEVE sold 17237.0 shares on Jan 03.
